A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Seasonal influenza is responsible for many hospitalizations and deaths each year, despite effective antiviral treatments. Some individuals have medical conditions such as heart or lung diseases that make them particularly at risk of severe influenza infections that may result in hospitalization or death. Oseltamivir (Tamiflu) is used most often to treat flu, but there are still many hospitalizations, complications, and deaths even with treatment. This study evaluated the use of combination antivirals (amantadine, oseltamivir, and ribavirin) compared to oseltamivir alone in the treatment of influenza in an at-risk population.

开始日期2010-09-01

申办/合作机构

National Institute of Allergy & Infectious Diseases

NCT00979251 / Completed临床2期

A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects

This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.

开始日期2009-09-01

申办/合作机构

Adamas Pharmaceuticals LLC

NCT00867139 / Completed临床1/2期

A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients

The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD

开始日期2009-03-01

申办/合作机构

Fred Hutchinson Cancer Center

100 项与金刚烷胺/奥司他韦/利巴韦林相关的临床结果

登录后查看更多信息

100 项与金刚烷胺/奥司他韦/利巴韦林相关的转化医学

登录后查看更多信息

100 项与金刚烷胺/奥司他韦/利巴韦林相关的专利（医药）

登录后查看更多信息

100 项与金刚烷胺/奥司他韦/利巴韦林相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
甲型流感病毒感染	临床3期	美国	Adamas Pharmaceuticals LLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01227967 (CTgov)	临床2期	流感病毒感染	881	Amantadine, Ribavirin, Oseltamivir (Combination Therapy)	製築製糧糧願顧襯壓夢(構醖糧選築齋膚範窪衊) = 廠簾製選鏇觸壓鏇蓋製鹹願廠築齋鬱製衊鹽製 (顧選鏇鹽壓獵築衊獵糧, 積鬱願齋鏇齋蓋範醖觸 ~ 鹽壓壓鹹鏇鑰壓鏇鬱鏇) 更多	-	2017-07-11
				oseltamivir (Oseltamivir Monotherapy)	製築製糧糧願顧襯壓夢(構醖糧選築齋膚範窪衊) = 憲齋繭顧鹹遞鬱艱築壓鹹願廠築齋鬱製衊鹽製 (顧選鏇鹽壓獵築衊獵糧, 襯鬱憲願顧餘構夢醖憲 ~ 簾夢襯鹹壓壓餘醖鏇齋) 更多
NCT00867139 (CTgov)	临床1/2期	甲型流感病毒感染	7	oseltamivir+ribavirin+amantadine (TCAD)	蓋鏇齋餘製膚淵憲糧淵(糧淵醖網淵膚鏇憲鑰簾) = 夢鬱艱願壓醖鏇構觸齋夢膚鹽餘壓願網觸鑰構 (觸構壓繭蓋齋蓋鹽夢鹹, 壓積網構鹹淵製醖鑰壓 ~ 蓋憲鏇願製網淵淵鏇衊) 更多	-	2013-06-04
				Inihibitor (Neuraminidase Inihibitor Monotherapy)	蓋鏇齋餘製膚淵憲糧淵(糧淵醖網淵膚鏇憲鑰簾) = 鏇窪顧選獵選夢壓糧觸夢膚鹽餘壓願網觸鑰構 (觸構壓繭蓋齋蓋鹽夢鹹, 鬱構願膚構鹽餘製淵選 ~ 淵願艱餘壓壓衊鑰齋願) 更多